VERAPAMIL HYDROCHLORIDE capsule, delayed release pellets

Country: মার্কিন যুক্তরাষ্ট্র

ভাষা: ইংরেজি

সূত্র: NLM (National Library of Medicine)

সক্রিয় উপাদান:

VERAPAMIL HYDROCHLORIDE (UNII: V3888OEY5R) (VERAPAMIL - UNII:CJ0O37KU29)

থেকে পাওয়া:

Carilion Materials Management

INN (International Name):

VERAPAMIL HYDROCHLORIDE

রচনা:

VERAPAMIL HYDROCHLORIDE 180 mg

প্রশাসন রুট:

ORAL

প্রেসক্রিপশন টাইপ:

PRESCRIPTION DRUG

থেরাপিউটিক ইঙ্গিত:

Verapamil hydrochloride sustained-release capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmaco

পণ্য সারাংশ:

NDC:68151-0136-8 in a BOTTLE of 1 CAPSULE, DELAYED RELEASE PELLETSS Store at Controlled Room Temperature 20° to 25°C (68° to 77°F). [See USP]. Avoid excessive heat. Brief digressions above 25°C, while not detrimental, should be avoided. Protect from moisture. Dispense in tight, light-resistant container as defined in USP.

অনুমোদন অবস্থা:

New Drug Application

পণ্য বৈশিষ্ট্য

VERAPAMIL HYDROCHLORIDE- VERAPAMIL HYDROCHLORIDE CAPSULE, DELAYED
RELEASE PELLETS
CARILION MATERIALS MANAGEMENT
----------
VERAPAMIL HYDROCHLORIDE SUSTAINED-RELEASE CAPSULES
R ONLY
DESCRIPTION
Verapamil hydrochloride sustained-release capsules are calcium ion
influx inhibitors (slow channel
blockers or calcium ion antagonists). Verapamil hydrochloride
sustained-release capsules are available
for oral administration as a 360 mg hard gelatin capsule (lavender
cap/yellow body), a 240 mg hard
gelatin capsule (dark blue cap/yellow body), a 180 mg hard gelatin
capsule (light grey cap/yellow
body), and a 120 mg hard gelatin capsule (yellow cap/yellow body).
These pellet-filled capsules
provide a sustained-release of the drug in the gastrointestinal tract.
The structural formula of verapamil HCl is given below: C H N O •HCl
M.W.
491.07
Chemical name: Benzeneacetonitrile,
α-[3-[[2-(3,4-dimethoxyphenyl)-ethyl]methylamino]propyl]-3,4-
dimethoxy-α-(1-methylethyl), monohydrochloride.
Verapamil HCl is an almost white, crystalline powder, practically free
of odor, with a bitter taste. It is
soluble in water, chloroform and methanol. Verapamil HCl is not
structurally related to other
cardioactive drugs.
In addition to verapamil HCl the verapamil hydrochloride
sustained-release capsules contain the
following inactive ingredients: fumaric acid, talc, sugar spheres,
povidone, shellac, gelatin, FD&C red
#40, yellow iron oxide, titanium dioxide, methylparaben,
propylparaben, silicon dioxide, and sodium
lauryl sulfate. In addition, the verapamil hydrochloride
sustained-release capsules 240 mg and 360 mg
capsules contain FD&C blue #1 and D&C red #28; and the verapamil
hydrochloride sustained-release
capsules 180 mg contain black iron oxide.
CLINICAL PHARMACOLOGY
Verapamil hydrochloride sustained-release capsules are a calcium ion
influx inhibitor (slow channel
blockers or calcium ion antagonists) which exerts its pharmacologic
effects by modulating the influx of
ionic calcium across the cell membrane of the arterial smooth muscle
a